Zobrazeno 1 - 10
of 814
pro vyhledávání: '"Wim. J.G. Oyen"'
Autor:
Jorian P. Krol, MD, Tessa Veerbeek, MSc, Laura N. Deden, MSc, Frank B.M. Joosten, MD, PhD, Cornelis H. Slump, PhD, Wim J.G. Oyen, MD, PhD
Publikováno v:
Radiology Case Reports, Vol 18, Iss 8, Pp 2814-2822 (2023)
Four-dimensional computed tomography (4DCT) is one of the preoperative imaging modalities that can be used to localize a parathyroid adenoma in primary hyperparathyroidism patients however, sensitivity differs in literature and could be improved espe
Externí odkaz:
https://doaj.org/article/38425b11b2ec4e339d4b6584044ad3ae
Autor:
Miriam N. Mikhail Lette, Diana Paez, Lawrence N. Shulman, Mathias Guckenberger, Jean-Yves Douillard, Wim J.G. Oyen, Francesco Giammarile, Venkatesh Rangarajan, Michelle Ginsberg, Olivier Pellet, Zhongxing Liao, May Abdel Wahab
Publikováno v:
JCO Global Oncology, Vol , Iss 8 (2022)
PURPOSEKey to achieving better population-based outcomes for patients with lung cancer is the improvement of medical imaging and nuclear medicine infrastructure globally. This paper aims to outline why and spark relevant health systems strengthening.
Externí odkaz:
https://doaj.org/article/080da5bfee994b2e85df470c6fffddc1
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging, 50, 7, pp. 1929-1939
Adams, H, van de Garde, E M W, Vugts, D J, Grutters, J C, Oyen, W J G & Keijsers, R G 2023, ' [89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis : a phase 2 trial ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 50, no. 7, pp. 1929-1939 . https://doi.org/10.1007/s00259-023-06143-1
European Journal of Nuclear Medicine and Molecular Imaging, 50(7), 1929-1939. Springer Verlag
European Journal of Nuclear Medicine and Molecular Imaging, 50, 1929-1939
Adams, H, van de Garde, E M W, Vugts, D J, Grutters, J C, Oyen, W J G & Keijsers, R G 2023, ' [89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis : a phase 2 trial ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 50, no. 7, pp. 1929-1939 . https://doi.org/10.1007/s00259-023-06143-1
European Journal of Nuclear Medicine and Molecular Imaging, 50(7), 1929-1939. Springer Verlag
European Journal of Nuclear Medicine and Molecular Imaging, 50, 1929-1939
Introduction Immune-mediated interstitial pneumonitis may be treated with anti-CD20 therapy after failure of conventional therapies. However, clinical response is variable. It was hypothesized that autoreactive CD20-positive cells may play an importa
Autor:
Ivalina Hristova, Ronald Boellaard, Paul Galette, Lalitha K. Shankar, Yan Liu, Sigrid Stroobants, Otto S. Hoekstra, Wim J.G. Oyen
Publikováno v:
EJNMMI Physics, Vol 4, Iss 1, Pp 1-15 (2017)
Abstract To date, there is no published detailed checklist with parameters referencing the DICOM tag information with respect to the quality control (QC) of PET/CT scans. The aims of these guidelines are to provide the know-how for effectively contro
Externí odkaz:
https://doaj.org/article/acac743d08c64048a58a598a366a2207
Autor:
Carla M.L. van Herpen, Wim J.G. Oyen, Erik H.J.G. Aarntzen, Winette T.A. van der Graaf, Gerben J.C. Zwezerijnen, Otto S. Hoekstra, Peter F.A. Mulders, Bertha Eisses, Adrienne H. Brouwers, Anne I.J. Arens, Astrid A.M. van der Veldt, C. Willemien Menke-van der Houven van Oordt, Ingrid M.E. Desar, Sandra Heskamp, Lindsay Angus, Sophie L. Gerritse, Suzanne C. van Es, Sjoerd G. Elias, Sjoukje F. Oosting, Sarah R. Verhoeff
Lasso model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a247ec4ea06246a4709494c1fa5dbaa5
https://doi.org/10.1158/1078-0432.22489035
https://doi.org/10.1158/1078-0432.22489035
Autor:
Carla M.L. van Herpen, Wim J.G. Oyen, Erik H.J.G. Aarntzen, Winette T.A. van der Graaf, Gerben J.C. Zwezerijnen, Otto S. Hoekstra, Peter F.A. Mulders, Bertha Eisses, Adrienne H. Brouwers, Anne I.J. Arens, Astrid A.M. van der Veldt, C. Willemien Menke-van der Houven van Oordt, Ingrid M.E. Desar, Sandra Heskamp, Lindsay Angus, Sophie L. Gerritse, Suzanne C. van Es, Sjoerd G. Elias, Sjoukje F. Oosting, Sarah R. Verhoeff
Score chart with predicted probability (%) to remain on WW at 12 months This model was based on the number of IMDC Risk factors (0, 1, 2), the number or involved organ sites (0 - 4) and the geometric mean [¹⁸F]FDG SUVmax as a continuous variable.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::024dde545016efb5249512402f68978b
https://doi.org/10.1158/1078-0432.22489029
https://doi.org/10.1158/1078-0432.22489029
Autor:
Carla M.L. van Herpen, Wim J.G. Oyen, Erik H.J.G. Aarntzen, Winette T.A. van der Graaf, Gerben J.C. Zwezerijnen, Otto S. Hoekstra, Peter F.A. Mulders, Bertha Eisses, Adrienne H. Brouwers, Anne I.J. Arens, Astrid A.M. van der Veldt, C. Willemien Menke-van der Houven van Oordt, Ingrid M.E. Desar, Sandra Heskamp, Lindsay Angus, Sophie L. Gerritse, Suzanne C. van Es, Sjoerd G. Elias, Sjoukje F. Oosting, Sarah R. Verhoeff
Purpose:Watchful waiting (WW) can be considered for patients with metastatic clear-cell renal cell carcinoma (mccRCC) with good or intermediate prognosis, especially those with 18F]FDG PET/CT and [89Zr]Zr-DFO-girentuximab PET/CT for WW duration in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0d98d95deb14bae81ed33d1c0ff2717
https://doi.org/10.1158/1078-0432.c.6532866
https://doi.org/10.1158/1078-0432.c.6532866
Autor:
Conny J. van der Laken, Wim J.G. Oyen, Chantal A M Bouman, Martin Gotthardt, Noortje van Herwaarden, Annelies B. Blanken, Cornelia H. M. van den Ende, Alfons A den Broeder, Aatke van der Maas
Publikováno v:
Rheumatology, 61, SI, pp. SI6-SI13
Rheumatology (Oxford, England), 61(SI), SI6-SI13. Oxford University Press
Rheumatology, 61, SI6-SI13
Bouman, C A M, van Herwaarden, N, Blanken, A B, van der Laken, C J, Gotthardt, M, Oyen, W J G, den Broeder, A A, van der Maas, A & van den Ende, C H 2022, ' 18F-FDG PET-CT in rheumatoid arthritis patients tapering TNFi : reliability, validity and predictive value ', Rheumatology (Oxford, England), vol. 61, no. SI, pp. SI6-SI13 . https://doi.org/10.1093/rheumatology/keab842
Rheumatology (Oxford, England), 61(SI), SI6-SI13. Oxford University Press
Rheumatology, 61, SI6-SI13
Bouman, C A M, van Herwaarden, N, Blanken, A B, van der Laken, C J, Gotthardt, M, Oyen, W J G, den Broeder, A A, van der Maas, A & van den Ende, C H 2022, ' 18F-FDG PET-CT in rheumatoid arthritis patients tapering TNFi : reliability, validity and predictive value ', Rheumatology (Oxford, England), vol. 61, no. SI, pp. SI6-SI13 . https://doi.org/10.1093/rheumatology/keab842
Objectives To investigate the reliability and validity of fluorine-18 fluorodeoxyglucose (18F-FDG) PET-CT scanning (FDG-PET) in RA patients with low disease activity tapering TNF inhibitors (TNFis) and its predictive value for successful tapering or
Autor:
Carl G. Figdor, Cornelis J.A. Punt, Gosse J. Adema, Sophie Lucas, Otto C. Boerman, Wim J.G. Oyen, Roel Mus, Michelle M. van Rossum, Sandra Croockewit, Annemiek J. de Boer, Mandy W.M.M. van de Rakt, Nicole M. Scharenborg, Joannes F.M. Jacobs, Erik H.J.G. Aarntzen, Annechien J.A. Lambeck, Gerty Schreibelt, I. Jolanda M. de Vries, W. Joost Lesterhuis
PDF file - 41K, Clinical protocol and immunization schedule.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e8f6b0408be93f19ee1f70b11151f57
https://doi.org/10.1158/1078-0432.22442606.v1
https://doi.org/10.1158/1078-0432.22442606.v1
Autor:
Gabriela Kramer-Marek, Graham Smith, Wim J.G. Oyen, Kevin J. Harrington, Louis Allott, Daniela M. Ciobota, Rhodri Smith, Thomas A. Burley, Chiara Da Pieve, Carlos D. Martins
Representative 3D-rendering of segmented MCF-7, MDA-MB-468 and MDA-MB-231 xenografts following PET/CT image acquisition 3 h after 89Zr-DFO-ZHER3:8698 injection.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d18fd39f5aab8a016445ea75c5b6e5a
https://doi.org/10.1158/1078-0432.22464824
https://doi.org/10.1158/1078-0432.22464824